Emodin reduces the activity of (1,3)-beta-D-glucan synthase from Candida albicans and does not interact with caspofungin

• Autorzy: Janeczko M.
• Języki publikacji: EN

Abstrakty

EN

Candidiasis is the most common opportunistic yeast infection, with Candida albicans as a paramount causative species. (1,3)-β-D-glucan is one of the three main targets of clinically available antifungal agents used to treat Candida infections. It is one of the most abundant fungal cell wall components. Echinocandins represent the newest class of antifungals affecting cell wall biosynthesis through non-competitive inhibition of (1,3)-β-D-glucan synthase. Therefore, treatment with echinocandins causes defects in fungal cell integrity. In the present study, similar activity of emodin (6-methyl-1,3,8-trihydroxyanthraquinone) has been revealed. Many reports have already shown the antifungal potential of this pleiotropic molecule, including its activity against C. albicans. The aim of this report was to evaluate the activity of emodin towards a new molecular target, i.e. (1,3)-β-D-glucan synthase isolated from Candida cells. Moreover, given the identical mechanism of the activity of both molecules, interaction of emodin with caspofungin was determined. The study revealed that emodin reduced (1,3)-β-D-glucan synthase activity and increased cell wall damage, which was evidenced by both a sorbitol protection assay and an aniline blue staining assay. Furthermore, the synergy testing method showed mainly independence of the action of both tested antifungal agents, i.e. emodin and caspofungin used in combination.

Słowa kluczowe

EN

candidiasis; yeast infection; Candida albicans; caspofungin; (1,3)-beta-D-glucan synthase; antifungal agent

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2018
• Tom: 67
• Numer: 4
• Opis fizyczny: p.463-470,fig.,ref.

Twórcy

autor

Janeczko M.

• Department of Molecular Biology, The John Paul II Catholic University of Lublin, Lublin, Poland

Bibliografia

• Agarwal V, Lal P, Pruthi V. 2010. Effect of plant oils on Candida albicans. J Microbiol Immunol Infect. 43(5):447–451.
• Alves DS, Perez-Fons L, Estepa A, Micol V. 2004. Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. Biochem Pharmacol. 68:549–561.
• Apgar JM, Wilkening RR, Greenlee ML, Balkovec JM, Flattery AM, Abruzzo GK, Galgoci AM, Giacobbe RA, Gill CJ, Hsu MJ, et al. 2015. Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin. Bioorg Med Chem Lett. 25(24):5813–5818.
• Canela HMS, Cardoso B, Vitali LH, Coelho HC, Martinez R, Ferreira MEDS. 2018. Prevalence, virulence factors and antifungal susceptibility of Candida spp. isolated from bloodstream infections in a tertiary care hospital in Brazil. Mycoses. 61(1):11–21.
• Cao F, Peng W, Li X, Liu M, Li B, Qin R, Jiang W, Cen Y, Pan X, Yan Z, et al. 2015. Emodin is identified as the active component of ether extracts from Rhizoma Polygoni Cuspidati, for anti-MRSA activity. Can J Physiol Pharmacol. 93(6):485–493.
• Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 18(5):195–204.
• Denning DW. 2003. Echinocandin antifungal drugs. Lancet. 362(9390):1142–1151.
• Dong X, Fu J, Yin X, Cao S, Li X, Lin L; Huyiligeqi, Ni J. 2016. Emodin: A Review of its pharmacology, toxicity and pharmacokinetics. Phytother Res. 30(8):1207–1218.
• Frost DJ, Brandt KD, Cugier D, Goldman R. 1995. A whole-cell Candida albicans assay for the detection of inhibitors towards fungal cell wall synthesis and assembly. J Antibiot. 48(4):306–310.
• Hemaiswarya S, Kruthiventi AK, Doble M. 2008. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine. 15(8):639–652.
• Janeczko M, Masłyk M, Kubiński K, Golczyk H. 2017. Emodin, a natural inhibitor of protein kinase CK2, suppresses growth, hyphal development, and biofilm formation of Candida albicans. Yeast. 34:253–265.
• Kanafani ZA, Perfect JR. 2008. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 46(1):120–128.
• Kong WJ, Wang JB, Jin C, Zhao YL, Dai CM, Xiao XH, Li ZL. 2009. Effect of emodin on Candida albicans growth investigated by microcalorimetry combined with chemometric analysis. Appl Microbiol Biotechnol. 83(6):1183–1190.
• Lee HS, Kim Y. 2016. Antifungal activity of Salvia miltiorrhiza against Candida albicans is associated with the alteration of membrane permeability and (1,3)-β-D-Glucan synthase activity. J Microbiol Biotechnol. 26(3):610–617.
• Liu Z, Ma N, Zhong Y, Yang Zhan-qin Y. 2015. Antiviral effect of emodin from Rheum palmatus against coxaskievirus B5 and human respiratory syncytial virus in vitro. J Huazhong University Sci Technol (Medical Sciences). 35:916–922.
• Liu Z, Wei F, Chen LJ, Xiong HR, Liu YY, Luo F, Hou W, Xiao H, Yang ZQ. 2013. In vitro and in vivo studies of the inhibitory effects of emodin isolated from Polygonum cuspidatum on coxsakievirus b₄. Molecules. 18(10):11842–11858.
• Martins N, Ferreira IC, Barros L, Silva S, Henriques M. 2014. Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia. 177(5–6):223–240.
• Mayer FL, Wilson D, Hube B. 2013. Candida albicans pathogenicity mechanisms. Virulence. 4(2):119–128.
• Monisha BA, Kumar N, Tiku AB. 2016. Emodin and its role in chronic diseases. Adv Exp Med Biol. 928:47–73.
• Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 52(1):1.
• Petersen PJ, Labthavikul P, Jones CH, Bradford PA. 2006. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 57(3):573–576.
• Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 20(1): 133–163.
• Pianalto KM, Alspaugh JAJ. 2016. New horizons in antifungal therapy. J Fungi (Basel). 2:2(4).
• Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. 2013. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 62(1):10–24.
• Severance EG, Gressitt KL, Stallings CR, Katsafanas E, Schweinfurth LA, Savage CL, Adamos MB, Sweeney KM, Origoni AE, Khushalani S, et al. 2016. Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder. Schizophr. 2:16018.
• Shedletzky E, Unger C, Delmer DP. 1997. A microtiter-based fluorescence assay for (1,3)-beta-glucan synthases. Anal Biochem. 249(1): 88–93.
• Sher A. 2009. Antimicrobial activity of natural products from medicinal plants. Gomal J Med Sci. 7:72–78.
• Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, Sethi G. 2013. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 341(2):139–149.
• Singh N, Yeh PJ. 2017. Suppressive drug combinations and their potential to combat antibiotic resistance. J Antibiot (Tokyo). 70(11): 1033–1042.
• Vicente MF, Basilio A, Cabello A, Peláez F. 2003. Microbial natural products as a source of antifungals. Clin Microbiol Infect. 9(1):15–32.
• CLSI. 2017. Reference method for broth dilution antifungal susceptibility testing of yeasts. CLSI standard M27. 4th ed. Wayne (USA): Clinical and Laboratory Standards Institute.
• Wei WT, Lin SZ, Liu DL, Wang ZH. 2013. The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review). Oncol Rep. 30(6):2555–2562.
• Wiederhold NP. 2018. The antifungal arsenal: alternative drugs and future targets. Int J Antimicrob Agents. 51(3):333–339.
• Zacchino SA, Butassi E, Cordisco E, Svetaz LA. 2017. Hybrid combinations containing natural products and antimicrobial drugs that interfere with bacterial and fungal biofilms. Phytomedicine. 37:14–26.

Identyfikatory

DOI

10.21307/pjm-2018-054